A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe

Código QR

A novel model of molnupiravir against SARS-CoV-2 replication: accumulated RNA mutations to induce error catastrophe

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuxi Zhao, Gu He, Wei Huang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Publishing Group 2021
Materias:	Medicine R Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/132d342b889c49ae990bd2a7712464b5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
por: Ching-Chi Lee, et al.
Publicado: (2021)

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
por: Philippine Eloy, et al.
Publicado: (2021)

Temporal dynamics of SARS-CoV-2 mutation accumulation within and across infected hosts.
por: Andrew L Valesano, et al.
Publicado: (2021)

SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition
por: Jian Ma, et al.
Publicado: (2021)

Hotspot Mutations in SARS-CoV-2
por: Indrajit Saha, et al.
Publicado: (2021)

Antiviral Resistance against Viral Mutation: Praxis and Policy for SARS-CoV-2
por: Penner Robert
Publicado: (2021)

Molnupiravir; an effective drug in treating COVID-19?
por: Alireza Pouramini, et al.
Publicado: (2022)

Identification of Cellular Factors Required for SARS-CoV-2 Replication
por: Aleksandra Synowiec, et al.
Publicado: (2021)

Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
por: Jackelyn Murray, et al.
Publicado: (2021)

SARS-CoV-2 infection and replication in human gastric organoids
por: Giovanni Giuseppe Giobbe, et al.
Publicado: (2021)

Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
por: Tingting Li, et al.
Publicado: (2021)

Host-specific asymmetric accumulation of mutation types reveals that the origin of SARS-CoV-2 is consistent with a natural process
por: Ke-Jia Shan, et al.
Publicado: (2021)

Architecture of a SARS-CoV-2 mini replication and transcription complex
por: Liming Yan, et al.
Publicado: (2020)

Organ-specific genome diversity of replication-competent SARS-CoV-2
por: Jolien Van Cleemput, et al.
Publicado: (2021)

SARS-CoV-2 variant evolution in the United States: High accumulation of viral mutations over time likely through serial Founder Events and mutational bursts.
por: Rafail Nikolaos Tasakis, et al.
Publicado: (2021)

Natural Apocarotenoids and Their Synthetic Glycopeptide Conjugates Inhibit SARS-CoV-2 Replication
por: Ilona Bereczki, et al.
Publicado: (2021)

SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication
por: Yuchen Zhang, et al.
Publicado: (2021)

UV-C irradiation is highly effective in inactivating SARS-CoV-2 replication
por: Mara Biasin, et al.
Publicado: (2021)

SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography
por: Steffen Klein, et al.
Publicado: (2020)

Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance
por: Mohamed Fareh, et al.
Publicado: (2021)

Development of an Inactivated Vaccine against SARS CoV-2
por: Shaikh Terkis Islam Pavel, et al.
Publicado: (2021)

Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant
por: Sten Ilmjärv, et al.
Publicado: (2021)

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
por: Lin Yang, et al.
Publicado: (2021)

SARS-CoV-2 variants reveal features critical for replication in primary human cells.
por: Marie O Pohl, et al.
Publicado: (2021)

SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication
por: Soren Alexandersen, et al.
Publicado: (2020)

Emergent SARS-CoV-2 variants: comparative replication dynamics and high sensitivity to thapsigargin
por: Sarah Al-Beltagi, et al.
Publicado: (2021)

No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2
por: Lucy van Dorp, et al.
Publicado: (2020)

The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
por: Thushan I. de Silva, et al.
Publicado: (2021)

Comparison of the Characteristics of Cytokine Storm and Immune Response Induced by SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections
por: Liu T, et al.
Publicado: (2021)

Protections against the Risk of Airborne SARS-CoV-2 Infection
por: Clement J. McDonald
Publicado: (2020)

Antibody cocktail effective against variants of SARS-CoV-2
por: Kang-Hao Liang, et al.
Publicado: (2021)

Viral vector-based vaccines against SARS-CoV-2
por: Kenneth Lundstrom
Publicado: (2021)

A small interfering RNA (siRNA) database for SARS-CoV-2
por: Inácio Gomes Medeiros, et al.
Publicado: (2021)

In vivo structure and dynamics of the SARS-CoV-2 RNA genome
por: Yan Zhang, et al.
Publicado: (2021)

The architecture of the SARS-CoV-2 RNA genome inside virion
por: Changchang Cao, et al.
Publicado: (2021)

Structural basis of RNA cap modification by SARS-CoV-2
por: Thiruselvam Viswanathan, et al.
Publicado: (2020)

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
por: Pinja Jalkanen, et al.
Publicado: (2021)

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
por: Wayne Vuong, et al.
Publicado: (2020)

Characterization of Virus Replication, Pathogenesis, and Cytokine Responses in Syrian Hamsters Inoculated with SARS-CoV-2
por: Yang SJ, et al.
Publicado: (2021)

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
por: Kyle Rosenke, et al.
Publicado: (2021)